Drug Trial Radar · NCT01889251
A Phase III Study of A01016 in Subjects With Symptomatic Vitreomacular Adhesion
Last checked: Nov 20, 2026Latest source record: Nov 30, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
251
Actual
Start
Jul 2013
Primary completion
Sep 2014
Study completion Sep 2014
Sponsor
- Lead sponsor
- Alcon ResearchIndustry
- Sponsor type
- Industry
- First posted
- Jun 28, 2013
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 20 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the superiority regarding vitreomacular adhesion (VMA) resolution of a single intravitreal injection of A01016 (Ocriplasmin) compared to sham-injection in subjects with symptomatic VMA.
Conditions
- Symptomatic Vitreomacular Adhesion
Interventions
OcriplasminDrug
Sham injectionDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of Subjects With Non-Surgical Resolution of Vitreomacular Adhesion (VMA)Time frame: Day 28
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Contact Alcon for Trial Locations
Tokyo, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.